Drug Shortage Report for HEPARIN SODIUM INJECTION, USP

Last updated on 2023-03-01 History
Report ID 158765
Drug Identification Number 02392453
Brand name HEPARIN SODIUM INJECTION, USP
Common or Proper name Heparin Sodium Injection, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) HEPARIN SODIUM
Strength(s) 10000UNIT
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS
Packaging size 0.5mL
ATC code B01AB
ATC description ANTITHROMBOTIC AGENTS
Reason for shortage Other (Please describe in comments)
Anticipated start date
Actual start date 2023-01-05
Estimated end date 2023-03-01
Actual end date 2023-02-11
Shortage status Resolved
Updated date 2023-03-01
Company comments Fresenius Kabi Canada regrets to advise that due to unforeseen circumstances, we have encountered a supply interruption on our Heparin Sodium Injection, USP 10 000 USP units/mL SD Vial 0.5 mL effective immediately until March 1, 2023.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v11 2023-03-01 French Compare
v10 2023-03-01 English Compare
v9 2023-01-06 English Compare
v8 2023-01-05 French Compare
v7 2023-01-05 English Compare
v6 2023-01-02 French Compare
v5 2023-01-02 English Compare
v4 2022-11-03 French Compare
v3 2022-11-03 English Compare
v2 2022-04-13 French Compare
v1 2022-04-13 English Compare

Showing 1 to 11 of 11